At Outpost, our clinical-stage product candidate is in development for the treatment of stress urinary incontinence (SUI) and fecal incontinence (FI).
At Outpost, we are passionate about improving the lives of patients suffering from urologic and gastrointestinal disorders. By bringing innovative medicines to market, our goal is to truly advance patient care and quality of life. Our team of scientists and functional experts have extensive experience in drug development and commercialization, deep therapeutic expertise, and a shared commitment to scientific excellence and integrity. The company’s lead product candidate, OP-352, is being studied for the treatment of stress urinary incontinence (SUI), fecal incontinence (FI), and multiple other difficult-to-treat disorders. Over one-third of women will suffer from SUI in their lifetime and up to 20% of people over 65 years of age will experience FI. OP-352 offers a novel pharmacologic approach and has the potential to significantly improve the lives of millions of patients suffering from these disorders.